Clinical Trial Update: A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for giredestrant (GDC-9545) in postmenopausal women with operable stage I-III estrogen receptor-positive breast cancer; trial comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Giredestrant (giredestrant)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2023-03-10